NCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
Clinical Trials
9 trialsNCT05820763 2024-07-10
Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
Washington University School of Medicine
Phase 2 Withdrawn
NCT05952687 2024-03-27
Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors
St. Jude Children's Research Hospital
Phase 1 Withdrawn
NCT02389543 2023-01-26
SLAM
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT02628704 2023-01-26
SCORE
Karyopharm Therapeutics Inc
Phase 2 Withdrawn
NCT05170789 2022-05-04
ESdRRMM
Tulane University
Phase 2 Withdrawn
NCT05177276 2022-01-04
Selinexor Combination Ph 1 Study
Hackensack Meridian Health
Phase 1/2 Withdrawn
NCT03880123 2020-11-27
Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma
Columbia University
Phase 1 Withdrawn
NCT02536495 2015-10-30
Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 1/2 Withdrawn